Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "CABASTY Trial - Pain Response and HRQL Analysis in Patients With mCRPC Receiving Cabazitaxel Every 2 Weeks vs. Every 3 Weeks"

118 views
November 3, 2023
Comments 0
Login to view comments. Click here to Login